# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P001 | Small-activating RNA therapy development for the inherited genetic disorder Aniridia | Lina | Abdul Kadir | University of Liverpool |
| P002 | The Role of GW182 Proteins in Mediating Off-Target Activity of GalNAc-siRNAs | Saket | Agarwal | Alnylam Pharmaceuticals |
| P003 | Improving Yield by Optimizing Loading and Surface Area of CPG Solid Supports | Shireen | Ahmed | LGC Biosearch Technologies |
| P004 | Nuclear Localization Interferes with siRNA targeting of Mutant Huntington | Sarah | Allen | UMass Chan Medical School |
| P005 | Bicyclic peptide transferrin receptor 1 ligands conjugated to oligonucleotide therapeutics improve potency in skeletal and cardiac muscle | Brooke | Anderson | Ionis Pharmeuticals |
| P006 | Assessing hybridization dependent off-target risk for therapeutic oligonucleotides – updated recommendations | Patrik | Andersson | AstraZeneca R&D |
| P007 | Knockdown of hyperactivated LRRK2 by splice-switching antisense oligonucleotide (SSO)-mediated activation of nonfunctional pseudoexons | Brage | Andresen | University of Southern Denmark |
| P008 | Optimized splice-switching oligonucleotide-mediated knockdown of XDH for the treatment of Gout | Priya | Aneja | Deep Genomics Inc |
| P009 | microRNAs enhance dendritic cell reprogramming | Nejc | Arh | Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University |
| P010 | Impurity analysis of phosphoramidites for producing oligotherapeutics | Darwin | Asa | Thermo Fisher Scientific |
| P011 | Control of the Assembly and Disassembly of Spherical Nucleic Acids is Critical for Enhanced Gene Silencing | Jathavan | Asohan | McGill University |
| P012 | RNA-seq-based Nucleic Acid Therapeutics lead optimization | Nadine | Assmann | Axolabs GmbH |
| P013 | CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | Anna | Aviñó | IQAC-CSIC |
| P014 - V | Personalized Antisense Oligonucleotides for Pitt-Hopkins syndrome | Shalhevet | Azriel | Sheba Medical Center |
| P015 | Tissue pharmacokinetics of antisense oligonucleotides | Erica | Bäckström | AstraZeneca |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P016 | An Integrated Assessment of Systemic Effects from Intrathecal Administration of 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides | Brenda | Baker | Ionis Pharmaceuticals, Inc |
| P017 | Fluorine-Modified Antisense Oligonucleotides Targeting the C9orf72 Repeat Expansion in C9FTD/ALS | Halle | Barber | McGill University |
| P018 | ASO delivery via a TfR-binding transport vehicle achieves widespread and functional biodistribution in non-human primates | Scarlett | Barker | Denali Therapeutics |
| P019 | Selection of relevant species for a nonclinical program of an antisense oligo | Nuria | Barquero | ARTHEx Biotech |
| P020 | Antisense oligonucleotides targeting an oncogenic mitochondrial long non-coding eca-ASncmtRNA to inhibit equine skin tumor cells proliferation | Eric | Barrey | Université Paris-Saclay, INRAE, AgroParisTech |
| P021 | Optimization of the Deprotection Scheme for 5'Triphosphate RNA Oligonucleotides | Jennifer | Bartels | TriLink Biotechnologies |
| P022 | Bifunctional antisense oligonucleotides - potential in reduction of invasive phenotype of cancer cells | Natalia | Bartyś | Institute of Bioorganic Chemistry PAS |
| P023 | Advancements in Targeted Oligonucleotide Therapeutics for Splicing Correction in Erythropoietic Protoporphyria | J. Philipp | Becker | Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich |
| P024 | Thrombin-Binding Aptamer (TBA) Derivatives with One or Two Additional G-Tetrads: Properties and Potential Antiproliferative Activity | Daniela | Benigno | University of Naples Federico II. Department of Pharmacy |
| P025 | Targeting SARS-CoV-2 Genome Structure With Delivery-Enabled Morpholino Oligos | Scott | Bittner | Oregon State University |
| P026 | Next Generation RNAi Therapeutics using Three Stranded RNAi Technology | Craig | Blanchette | Switch Therapeutics |
| P027 | LncRNA Specific Considerations for Design and Optimization of ASOs for Therapeutic Development and Translation | Ana | Silva | HAYA Therapeutics SA |
| P028 | Purification Strategy Development for Oligonucleotides | Kayla | Borland | AstraZeneca |
| P029 | Enhancing RNA-Based Therapies: Optimized In-House Oligonucleotide Synthesis for in vitroScreening | Brianna | Bramato | UMass Chan Medical School |
| P030 | Upregulation of PGRN by ASOs targeting an upstream open reading frame | Johannes | Braun | Roche Innovation Center Basel \| RNAhub |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P031 | Validation of therapeutic siRNAs in hiPSc-derived FTDP-17 neuronal model of tauopathy | Ilaria | Brentari | University of Trento |
| P032 | de novo Synthesis of Nucleosides and Nucleoside Analogues | Robert | Britton | Simon Fraser University |
| P033 | RNA editing by recruiting endogenous ADAR using circular RNA guides to correct a hotspot of dominant-negative glycine substitutions causing collagen VI-related dystrophies | Astrid | Brull | Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health |
| P034 | Exploring the role of GalNAc-siRNA mediated knockdown of key liver ischemia-reperfusion injury targets and impact on transcriptomic signature | Julianna | Buchwald | RNA Therapeutics Institute, UMass Chan Medical School |
| P035 | Adapting AIMer-based RNA editing technology for application in CNS | Michael | Byrne | Wave Life Sciences |
| P036 | Effect of antimiR-23b on a knee OA rat model | Isabella | Castano | ARTHEx Biotech |
| P037 | Extended Nucleic Acid (exNA): A Platform Technology for Enhancing siRNA Efficacy and Tissue Accumulation in Vivo | Jillian | Caiazzi | UMass Chan Medical School |
| P038 | Predicting novel splicing variants of SYNGAP1 using machine learning predictors: implications for therapeutic oligonucleotides | Keri | Callegari | Deep Genomics |
| P039 | Expression of Mutant Cardiac Sarcomeric Proteins Via Viral Vector in Human Engineered Heart Tissue | Stuart | Campbell | Yale University |
| P040 | Identifying novel siRNA guide strand 5'-end modifications for enhanced chemical stability, potency, and extrahepatic in vivo RNAi activity | Theodore | Carrigan-Broda | UMass Chan Medical School |
| P041 | BigRNA: A Large Neural Network Enabling Accurate Oligonucleotide Design and Variant Effect Predictions | Albi | Celaj | Deep Genomics |
| P042 | Triterpenes as a novel class of endosomal escape enhancers for siRNA | Myriam | Cerezo-Magaña | Department of Clinical Sciences, Oncology, Faculty of Medicine, Lund University |
| P043 | Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy | Estefanía | Cerro-Herreros | Arthex Biotech |
| P044 | PYC-001, a peptide-conjugated phosphorodiamidate morpholino oligomers for the treatment of autosomal dominant optic atrophy | Tracy | Chai | PYC Therapeutics |
| P045 | Aptamer-based kit for the quantification of a specific microorganism | Pauline | Chevalier | DPM UMR 5063 UGA CNRS |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P046 | Bioorthogonal Conjugate Platform Development for In vivo Gene Editing and Therapy | Hyun Jung | Chung | Korea Advanced Institute of Science and Technology (KAIST) |
| P047 | Tethering chemistry modulates accumulation, distribution, and efficacy of divalent siRNA in the CNS | David | Cooper | University of Massachusetts Chan Medical School |
| P048 | Investigating peptide nucleic acids (PNAs) as antimicrobial agents against Fusobacterium nucleatum | Valentina | Cosi | HIRI |
| P049 | Isoform-specific siRNAs: A potential therapeutic approach for 4R tauopathies. | Giuseppina | Covello | University of Trento, Department of Cellular, Computational and Integrative Biology (CIBIO) |
| P050 | Isoform-specific siRNAs: A potential therapeutic approach for 4R tauopathies. | Giuseppina | Covello | University of Trento, Department of Cellular, Computational and Integrative Biology (CIBIO) |
| P051 | Unraveling Trinucleotide Repeat Disorders: Somatic Instability, Gene Expression, and Oligonucleotide Therapeutics | Raul | Cuellar | Karolinska Institutet |
| P052 | The next generation Phosphorodiamidate Morpholino Oligomers: Design and synthesis, biophysical properties and intracellular trafficking. | Arnab | Das | Indian Association for the Cultivation of Science. |
| P053 | VO659, a CAG repeat-targeting ASO, blocks translation of polyQ proteins in a CAG repeat length dependent and allele preferential manner | Rudie | Weij | VICO Therapeutics |
| P054 | In vivo metabolic stability, strand-bias and silencing activity of GalNAc-conjugated siRNAs carrying phosphorothioate linkage-free sense strands | Dhrubajyoti | Datta | Alnylam Pharmaceuticals |
| P055 | Investigating Chemically-Modified Short Activating RNAs to Increase Nuclease Stability and Gene Activation | Jean-Paul | Desaulniers | Ontario Tech University |
| P056 | Comprehensive assessment of potential hybridization-dependent off-target effects of ATX-01 including In Silico, In Vitro and In Vivo evaluation | Ana | Díaz-Maqueda | Arthex Biotech |
| P057 | Subcellular characterization of lipid nanoparticle-mediated cytosolic mRNA delivery | Hampus | Du Rietz | Department of Clinical Sciences, Division for Oncology, Lund University |
| P058 | Advancing High-Throughput Quantitative Gene Expression Analysis with a CRISPR/Cas9-Enabled Reporter System | Sarah | Duellman | Promega Corporation |
| P059 | Exploring the potential of a novel albumin-binding amphiphilic conjugate for improved siRNA delivery | Hassan | Fakih | RNA Therapeutics Institute - UMass Chan Medical School |
| P060 | Targeting the IRES structure of mRNA for modulating gene translation | Albert | Ferriol Monjo | University of Southampton |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P061 | Antisense oligonucleotides targeting the SARS-CoV-2 genome to inhibit viral replication | Christopher | Fitzpatrick | Université Paris-Saclay, INRAE, AgroParisTech, GABI |
| P062 | Genetically separating the roles of the m6A methyltransferase METTL16 in SAM homeostasis and U6 snRNA methylation | Juliana | Flaherty | University of Texas Southwestern Medical Center |
| P063 - V | Development of a novel SOD1 antisense therapy for SOD1-linked and sporadic ALS | Loren | Flynn | Perron Institute |
| P064 | Use of HPLC to investigate isomeric impurity profiles of oligonucleotides | Pilar | Franco | Chiral Technologies Europe |
| P065 | Assessing the Safety of Antisense Oligonucleotides Through Interrogating Changes in the RNA- Binding Proteome. | Alex | Fulton | MRC Toxicology Unit, University of Cambridge |
| P066 | Identification and comparison of the intracellular protein partners of different chemistries and design of antisense oligonucleotides by an AP-MS (affinity purification mass spectrometry) approach | Aris | Gaci | Université Paris-Saclay, UVSQ, Inserm, END-ICAP |
| P067 | 3-base long 2'-O-Methyl oligonucleotides are potent TLR7 and TLR8 modulators | Michael | Gantier | Hudson Institute of Medical Research |
| P068 | Sequence-dependent modulation of viral-driven inflammation by a non-targeting 2'-O-Me gapmer oligonucleotide | Michael | Gantier | Hudson Institute of Medical Research |
| P069 | Plasma pharmacokinetics of N-acetylgalactosamine-conjugated small interfering ribonucleic acids (GalNAc-conjugated siRNAs) | Peter | Gennemark | Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca |
| P070 | Exploring the Different Aspects of Morpholino Oligonucleotides to Overcome the Therapeutic Barriers. | Atanu | Ghosh | Indian Association for the Cultivation of Science |
| P071 | A side-by-side comparison of peptide-delivered antisense antibiotics employing different nucleotide mimics | Chandradhish | Ghosh | Helmholtz Institute of RNA-based Infection Research |
| P072 | Utilizing click chemistry to robustly link Ga-corrole to siRNA for dual therapeutic cancer therapy effect. | Ifrodet | Giorgees | University of Ontario Institute of Technology |
| P073 | Translating Genetic information into Target Validation Tools with Antisense Oligonucleotides | Felix | Gnerlich | Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca |
| P074 | Counteracting reactive oxygen species in models of Duchenne muscular dystrophy improves antisense-oligonucleotide mediated dystrophin recovery | Remko | Goossens | Leiden University Medical Center, department of Human Genetics |
| P075 | Investigating the impact of dystrophin restoration in the central nervous system of dystrophic mouse models | Aurélie | Goyenvalle | Université Paris-Saclay, UVSQ, Inserm, END-ICAP |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P076 | Enabling ribosome profiling for drug discovery | Nicola | Guzzi | Discovery Sciences, R&D, Astrazeneca |
| P077 | Investigational WVE-006, an RNA editing oligonucleotide for the treatment of Alpha-1 antitrypsin deficiency | Cynthia | Caracta | Wave Life Sciences |
| P078 | Towards Allele-Selective Gapmer ASO design | Emilio | Harris-Mostert | Department of Clinical Genetics, Erasmus MC |
| P079 | Allele-specific targeting strategies for polyglutamine spinocerebellar ataxias by antisense oligonucleotides in iPSC-derived models | Stefan | Hauser | German Center for Neurodegenerative Diseases (DZNE) |
| P080 | Targeted delivery and functional validation of siRNA via purified extracellular vesicle | Xinjun | He | Vesicure Therapeutics |
| P081 | Improving APOBEC3 oligonucleotide inhibitors using sugar and phosphate modifications | Adam | Hedger | RNA Therapeutics Institute, University of Massachusetts Chan Medical School |
| P082 | Positional Impact of siRNA Chemical Modification Patterns on Ago Loading Efficiency | Samuel | Hildebrand | UMass Chan Medical School |
| P083 | Selective tumour cell killing with novel modular antibody-conjugate using self assembling nanostructures | Tina-Thien | Ho | University of Southampton |
| P084 | De novo Protein Interactome Profiling of Oligonucleotide Drugs | Daniel | Hofacker | University of Tübingen, Interfaculty Institute of Biochemistry |
| P085 | Investigating the Effects of Nuclear RNAi on Genome Stability | Cristina | Hofman | UT Southwestern Medical Center |
| P086 | PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 (DM1) | Ashling | Holland | PepGen Inc. |
| P087 | Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrate Potential for the Treatment of Duchenne Muscular Dystrophy (DMD) | Jaya | Goyal | PepGen Inc. |
| P088 | Three Novel Enhanced Delivery Oligonucleotide Candidates for Duchenne Muscular Dystrophy Mediate High Levels of Exon 53, 45, and 44 Skipping | Ashling | Holland | PepGen |
| P089 | Enhanced Delivery Oligonucleotide (EDO): Characterization of nuclear uptake that enabled engagement with target transcripts and show activity | Jaya | Goyal | PepGen Inc |
| P090 | Withdrawn | | | |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P091 | RNase H1 Involvement in cEt ASO-Induced Toxicity in the CNS | Jill | Hsiao | Ionis Pharmaceuticals |
| P092 | Exploring antisense oligonucleotide strategy for CDKL5 deficiency disorder | Yu-Han | Huang | Division of Genetics and Genomics, Boston Children's Hospital |
| P093 | Increasing specificity of microRNA 34a for its target HNF4α mRNA for treatment of cancer | Ting | Huang | Karolinska Institutet |
| P094 | Expanding genomic diversity of in vitro cellular models for robust discovery of therapeutic oligonucleotides | Martin | Jacko | Aperture Therapeutics |
| P095 | Withdrawn | | | |
| P096 | Mechanistic Origin of ADAR Inhibition by Site-specific LNA Modification in RNA Editing Substrates | Victorio | Jauregui-Matos | University of California, Davis |
| P097 | Preclinical development of VIO-01, a pan-DDR DNA decoy mediating DNA repair abrogation and unleashing the anti-tumor immune response. | Wael | Jdey | Valerio Therapeutics |
| P098 | Is continued genetic toxicology testing of therapeutic oligonucleotides containing well precedented modifications warranted? | Lene | Jensen | Novo Nordisk |
| P099 | Visualization of lipid nanoparticle disintegration and localized endosomal membrane damage | Johanna | Johansson | Department of Clinical Sciences, Section for Oncology and Pathology |
| P100 | TraffikGene: a novel platform for nucleic acid delivery based on amphiphilic peptide carriers | Marisa | Juanes | Universidad de Santiago de Compostela |
| P101 | Complete Restoration of Mucociliary Transport in Primary Ciliary Dyskinesia Patient Cells with Therapeutic Oligonucleotides | Silvia | Kreda | The University of North Carolina |
| P102 | Visualizing the interaction between anti-miRNA oligonucleotide and target miRNA using FRET | Yukiko | Kamiya | Kobe Pharmaceutical University |
| P103 | Targeted NFκB decoy oligodeoxynucleotide as a radiation sensitizer for human B-cell lymphoma | Damian | Kaniowski | Department of Immuno-Oncology at Beckman Research Institute at City of Hope Comprehensive Cancer Center |
| P104 | DeepMirBind: A Deep Learning Approach for MicroRNA Target Site Prediction and Design of Upregulation Oligonucleotides | Bhargav | Kanuparthi | Deep Genomics |
| P105 | Effects of Aicardi Goutières Syndrome-causing Mutations on Catalysis of Adenosine Deamination by ADAR1. | Agya | Karki | UC Davis |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P106 | Meta-analysis: Similar pharmacokinetics and tissue distribution of five GalNac-conjugated siRNAs administered IV or SC to mice | Ditte | Karpf | Novo Nordisk |
| P107 | Heteroduplex oligonucleotide technology that enables mitigation of neurotoxicity by antisense oligonucleotides | Maho | Katsuyama | Department of Neurology and Neurological Science, Tokyo Medical and Dental University |
| P108 - V | Sequence-Controlled Spherical Nucleic Acids: Gene Silencing, Encapsulation, and Cellular Uptake | Sepideh | Kaviani | McGill University |
| P109 | Investigations into mRNA LNP shelf-life stability under non-frozen conditions | Michael | Keller | F. Hoffmann-La Roche |
| P110 | Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding | Michael | Keller | F. Hoffmann-La Roche |
| P111 | Scalable One-Pot Liquid Phase Oligonucleotide Synthesis Enhanced By Organic Solvent Nanofiltration | Ronan | Kelly | UCD School of Chemical and Bioprocess Engineering |
| P112 | The Endosomal Escape Vehicle (EEV™) Platform Enhances the Delivery of Oligonucleotides to Skeletal and Cardiac Muscle | Mahboubeh | Kheirabadi | Entrada Therapeutics |
| P113 | Evaluation of Linker Chemistry in Peptide-Conjugated Morpholino Oligos | Mahsa | Khoshbakht | Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University |
| P114 | Exhaustive off-target profiling of gapmers with Target Variant Sequencing | Łukasz | Kiełpiński | Roche Pharma Research and Early Development |
| P115 | Enhancer RNAs stimulate Pol II pause release by harnessing multivalent interactions to NELF | Seung-Kyoon | Kim | Department of Convergent Bioscience and Informatics, Chungnam National University (CNU) |
| P116 | Functional coordination of BET family proteins in brain plasticity | Seung-Kyoon | Kim | Department of Convergent Bioscience and Informatics, Chungnam National University (CNU) |
| P117 | Trafficking and Target Gene Knockdown of Antisense Oligonucleotides Delivered by an Oligonucleotide Transport Vehicle (OTV) | Chaeyoung | Kim | Denali Therapeutics, Inc. |
| P118 | Development of a novel cell-penetrating asymmetric siRNA platform for targeting extrahepatic organs | June Hyun | Park | OliX Pharmaceuticals, Inc. |
| P119 | Synthesis of a ligand-conjugated ASOs library based on the Ugi reaction and exploration for novel ligands suitable for delivery of ASOs | Ryosuke | Kita | Graduate School of Pharmaceutical Sciences, Osaka University |
| P120 | Distracting DNA Binding Proteins Using Lipid Conjugated Oligonucleotides: A Potential Anticancer Therapeutic Application | Faith | Kivunga | Université de Bordeaux |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P121 | Withdrawn | | | |
| P122 | Oligonucleotide-Based Telomere Disruptor for Therapy of Hematologic Malignancies | Marcin | Kortylewski | Beckman Research Institute at City of Hope |
| P123 | RNA ACTIVATION OF A TRANSCRIPTION FACTOR INDUCES TERMINAL DIFFERENTIATION OF BLOOD CANCER IN PRECLINICAL STUDIES | Olivia | Kovecses | McGill University |
| P124 | Precision siRNA-based Immunosuppression for Graft-versus-Host Disease | Anastasia | Kremer | Uniklinikum |
| P125 | Small circular interfering RNAs (sciRNAs) | Jayanta | Kundu | Alnylam Pharmaceuticals |
| P126 | Evaluation of KD activity by systemic and local administration using branched lipid conjugated siRNA | Norikazu | Kuroda | SHIONOGI & Co., Ltd |
| P127 | Inhibition of SARS-CoV-2 by siRNA targeting the leader sequence and and development of bioprinted lung models for the study of virus biology | Jens | Kurreck | Technische Uni Berlin |
| P128 | Human in vitro toolbox for ASO-screening and neurotoxicity studies | Marlen | Lauffer | Leiden University Medical Center |
| P129 | Evaluation of modified nucleic acid analogues for splice modulation | Bao | Le | Murdoch University |
| P130 | Inhibition of GDNF family receptor α–like (GFRAL) expression in the hindbrain by RNA-targeted therapeutics | Minhee | Lee | THOR therapeutics, 701, W1, 99 Daehak-ro, Yuseong-gu |
| P131 | Threose Nucleic Acid – a potential next generation sugar chemistry | Meiling | Li | Roche Innovation center Basel |
| P132 | Stereodefined Phosphorodithioate LNA gapmers - Investigating discovery strategies and pharmacological properties | Meiling | Li | Roche Pharma Research and Early Development, Therapeutic Modalities, RNA Therapeutics, Roche Innovation Center Basel, F. Hoffmann-La Roche |
| P133 | Regenerative medicine for Parkinson's disease using splice-switching antisense oligonucleotides | Dunhui | Li | Murdoch University |
| P134 | Therapeutic development of saRNA for Duchenne muscular dystrophy by targeted activation of utrophin | Long-Cheng | Li | Ractigen Therapeutics |
| P135 | siRNA-ACO is a convenient modality for target mRNA knockdown in CNS tissue via local injection | Robert | Place | Ractigen Therapeutics |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P136 | Exon Skipping and Dystrophin Production with ENTR-601-45, a Novel EEV-Conjugated, Exon 45 Skip Amenable PMO in Preclinical Models of DMD | Xiang | Li | Entrada Therapeutics |
| P137 | Dynamin-2 (DNM2) targeting antisense oligonucleotides as a potential treatment for centronuclear myopathy (CNM) | Noa | Liberman-Isakov | Sarepta Therapeutics |
| P138 | Oligocarrier: A Promising Approach for siRNA Delivery | Natalie | Bao Ying | Nanyang Technological University |
| P139 | Systemic treatment with a lipophilic-conjugated antimiR-23b rescues functional and molecular phenotypes of DM1 cognitive dysfunction in the DMSXL mice. | Beatriz | Llamusi | Arthex Biotech |
| P140 | Comprehensive, scalable development of patient-customized ASOs for ataxia teleangiectasia | Clemens | Lochmann | Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research |
| P141 | Evaluation of antisense oligonucleotides targeting DMPK through digital PCR and in-cell western techniques. | Andrea | Lopez-Martinez | Nucleic Acid Therapeutics for Rare Diseases (NAT-RD), Biobizkaia Health Research Institute |
| P142 | Deep learning-based design of cell-targeting ligands enables functional siRNA delivery in multiple extrahepatic tissues | Ky | Lugo | Nosis Bio |
| P143 | Iminothioindoxyl-C-Nucleoside Based Quencher Systems for Oligonucleotide Applications | Larita | Luma | Goethe University |
| P144 | Multiplex immunoassay for spatial and quantitative interrogation of siRNA activity, delivery, and trafficking | Michael | Ly | Janssen |
| P145 | Transcript-selective induction of translational readthrough across disease-causing premature stop codons | Sandeep | Eswarappa | Indian Institute of Science |
| P146 | Spacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry | Luis | Macias | Verve Therapeutics |
| P147 | Targeting exonic cryptic splice variants in neurological disease by patient-customized splice modulation ASOs: the example of Ataxia Telangiectasia | Aline | Mack | Division for Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tuebingen |
| P148 | A chemical approach toward 2-fluoro-6-amino purine- and iso-guanine-containing oligonucleotides | Mimouna | MADAOUI | Alnylam Pharmaceutical |
| P149 | Evaluating gene editing for the treatment of erythropoietic protoporphyria | Eva-Maria | Manz | ETH Zurich |
| P150 | Delivery of Oligonucleotide Therapeutic Drugs: Universal Detection Reagents Specific for Nucleic Acid Modifications | Carl | Ascoli | Rockland Immunochemicals, Inc. |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P151 | Splice-switching antisense oligonucleotides correct PAH exon 11 skipping defects that cause phenylketonuria | Ainhoa | Martinez-Pizarro | Centro de Biología Molecular Severo Ochoa |
| P152 | Unleashing the Future: Pioneering new Ionizable Lipids and LNP Formulations enable targeted oligonucleotide delivery with outstanding in vivo performance | Diego | de Miguel | Certest Biotec |
| P153 | RNA Targeting of Predictive Biomarkers for Efficacy of Cytarabine in Acute Myeloid Leukemia Therapeutics | Bruktawit | Maru | McGill University |
| P154 | Silence of the fish: Injection of photoswitchable short interfering RNA oligonucleotides into Japanese medaka embryos (Oryzias latipes) to reversibly photochemically control gene silencing | Makenzie | Mateus | Ontario Tech University |
| P155 | Exploring an antisense oligonucleotide exon-skipping therapeutic strategy for Mucolipidosis II | Liliana | Matos | Research and Development Unit, Department of Human Genetics, INSA |
| P156 | Polycyclic Light-activatable Molecular Beacons | Vivien | McKenney | Goethe University |
| P157 | Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins | Zdravka | Medarova | TransCode Therapeutics, Inc. |
| P158 | Utilization of a Pharmacokinetic (PK) Model for STK-001 in Patients with Dravet Syndrome (DS) To Support the Selection of Dosing Regimens in Clinic | Meena | Meena | Stoke Therapeutics |
| P159 | Genome-wide CRISPR screen to uncover protein modulators of melanoma-targeted ASOs | Grégory | MENCHON | INSERM - OSS U1242 |
| P160 | In silico and in vitro investigation of gene targetability and knockdown kinetics by LNA-modified antisense oligonucleotides | Sven | Michel | Secarna Pharmaceuticals GmbH & Co. KG |
| P161 | Non-B DNA in Friedreich's Ataxia as target for anti-gene therapeutic oligonucleotides. | Salomé | Milagres | Department of Laboratory Medicine, TRACK, Karolinska Institutet, Karolinska University Hospital Institutet |
| P162 | Divalent Cation Buffering of Oligonucleotides for CNS Delivery Prevents Neurotoxicity | Rachael | Miller | UMass Chan Medical School |
| P163 | Anti-tumor nucleic acid delivery to the tumor site by RION of nucleic acid nanoparticle | Noriko | Miyamoto | 1247, yachigusa, yakusa |
| P164 | Artificial intelligence-based nonlinear sequence environment encapsulation yields robust native context therapeutic siRNA potency prediction algorithm | Kathryn | Monopoli | RNA Therapeutics Institute, UMass Chan Medical School |
| P165 - V | Antisense Oligonucleotides for Ultra-Rare Diseases – A Multidisciplinary Approach, From Patient to Treatment | Nofar | Mor | Sheba Medical Center, Wohl Institute of Translational Medicine |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P166 - V | Exploiting antisense oligonucleotides and the RNAi pathway to suppress esophageal cancer cells | Sharif | Moradi | Royan Institute for Stem Cell Biology and Technology |
| P167 | A Novel Approach for Site-Specific RNA Methylation Using Short Modified Oligonucleotides | Štefan | Moravčík | ETH |
| P168 | Large-scale expansions of Friedreich's ataxia GAA•TTC repeats in an experimental human system: role of DNA replication and prevention by LNA-DNA oligonucleotides and PNA oligomers | Negin | Mozafari | Karolinska Institutet |
| P169 | Therapeutic targeting of a MicroRNA in Duchenne Muscular Dystrophy and Heart Failure | Anders | Naar | Elenae Therapeutics, Inc. and University of California, Berkeley |
| P170 | Heteroduplex oligonucleotide technology boosts splice switching activity of morpholino in a Duchenne muscular dystrophy mouse model | Tetsuya | Nagata | Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University |
| P171 | Clinical proof of concept for anti-FGF2 aptamer therapy in exudative age-related macular degeneration: phase 1 and phase 2 trials in treatment-naïve and anti-VEGF pretreated patients | Yoshikazu | Nakamura | IMS University of Tokyo |
| P172 | Comprehensive approach to upregulate and stabilize frataxin mRNA using antisense oligonucleotides | Marek | Napierala | UT Southwestern Medical Center |
| P173 | Customized DNA Origami for Delivery of Therapeutic Oligonucleotides: Overcoming Challenges and Unlocking New Therapeutic Avenues | Natalia | Navarro | Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) |
| P174 | Employing antisense oligomers to repress the genotoxic activity of colibactin producing E. coli | Sarah | Nentwich | Institute of Molecular Infection Biology, University of Würzburg |
| P175 | AJIPHASE® Liquid-Phase Manufacturing Process and Ajico's Original Enzyme-Based Biotechnology for High-Purity siRNA Synthesis | Anna | Niwa | Ajinomoto Co., Inc. |
| P176 | Studies of interactions between aptamers/antibodies and bacteria by flow cytometry | Juliette | Nourry | UGA |
| P177 | Implementation of SplintR ligation qPCR as novel bioanalytical method for tissues quantification of oligonucleotide therapeutics for the expansion of the Evotec oligonucleotide drug discovery platform | Jacopo | Oieni | Aptuit, an Evotec company |
| P178 | Oncolytic Hairpin Nucleic Acid Pairs | Akimitsu | Okamoto | Department of Chemistry and Biotechnology, The University of Tokyo |
| P179 | Investigating the biophysical properties and in vivo activity of 7',5'-alpha-bicyclo-DNA backbone antisense oligonucleotides | Remya | Raghavan-Nair | NATA |
| P180 | Peptide-conjugated phosphorodiamidate morpholino oligomers for the treatment of Late-Onset Pompe Disease | Ryan | Oliver | Sarepta Therapeutics |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P181 | Pan-coronavirus siRNA effective against SARS-CoV-2 | YI-CHUNG | CHANG | Oneness Biotech Company |
| P182 | Assessment of Subtle HOS Changes in Oligonucleotide Therapeutics Using High-Throughput Circular Dichroism Spectrometer HTCD Plus and a program qHOS | Taiji | Oyama | JASCO Corporation |
| P183 | Elucidating the targets for improving the delivery of ASOs through genetic screens | Anwit | Pandit | MRC Toxicology Unit, University of Cambridge |
| P184 | OligoPhore and SemaPhore: deLIVERING therapeutic RNA | Covadonga | Paneda | Altamira Therapeutics |
| P185 | Liquid Phase Oligonucleotide Manufacture by Nanostar Sieving | Catalina | Parga | Exactmer |
| P186 | Uptake of chemically modified antagomirs by lung relevant cell systems. | Clement | Paris | AstraZeneca |
| P187 | Therapeutic development of OLX702A for NASH with Fibrosis and Obesity | June Hyun | Park | OliX Pharmaceuticals |
| P188 | Development of cell-penetrating asymmetric siRNA therapeutics by leveraging advanced ocular platform technology against various retinal diseases | June Hyun | Park | OliX Pharmaceuticals |
| P189 | Explainable AI: Designing better molecules to become drugs | Lykke | Pedersen | Abzu |
| P190 | Advancing In Vivo modeling and delivery systems for triplet repeat expansion-mediated corneal endothelial dystrophy: Implications for AntimiR therapy. | Diego | Piqueras-Losilla | ARTHEx Biotech |
| P191 | Withdrawn | | | |
| P192 | A global search for high-susceptibility targets of programmable RNA antibiotics | Linda | Popella | Institute of Molecular Infection Biology (IMIB), University of Wuerzburg |
| P193 | Developing Antisense Oligonucleotide-based Therapy for Osteosarcoma | Bal Hari | Poudel | CMMIT, Murdoch University |
| P194 | Preclinical evaluation of JAK2 specific investigational oligonucleotide for the treatment of MPNs | Bartlomiej | Przychodzen | Vanda Pharmaceuticals Inc. |
| P195 | A Platform for Controlled Template-Independent Enzymatic Synthesis of RNA Oligonucleotides | Dominic | Rainone | EnPlusOne Biosciences |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P196 - V | Developing ASO Treatment for a Bainbridge-Ropers Syndrome Patient | Shaul | Raviv | Cancer Research Center and Wohl Centre for Translational Medicine, Sheba Medical Center |
| P197 | The drug discovery journey for a patient with Dup15q Syndrome | Roxana | Redis | Charles River Laboratories |
| P198 | Development of an in vitro panel for neurotoxicity assessment of drug discovery candidates | Roxana | Redis | Charles River Laboratories |
| P199 | Exploring the stability of RNA-based delivery scaffolds in diverse biological matrices: methodology and implications for platform development | Laura | Reyes | Sixfold Bioscience |
| P200 | “Preclinical development of gapmers against a new therapeutic target in Myotonic Dystrophy” | Natalia | Riedel | Translational Genomics Group, BIOTECMED, University of Valencia |
| P201 | Characterization of immunestimulatory potential of LNA-modified antisense oligonucleotides | Irene | Riera Tur | Secarna Pharmaceuticals GmbH & Co. KG |
| P202 | RNAi-Mediated Silencing of SOD1 as a Therapy for ALS | Iris Valeria | Rivera Flores | Umass Chan Medical School |
| P203 | Synthesis, Characterization, and Biological Evaluation of Novel 3-Component Lipid Nanoparticles for mRNA Delivery | Joshua | Robinson | UT Southwestern Medical Center |
| P204 | Amide-Modified Oligonucleotides for Chemical Control of Functional RNAs | Eriks | Rozners | Binghamton University |
| P205 | Chemically modified microRNA mimics as oligonucleotide therapeutics: a case-study on miR-200c. | Anna | Rydzik | AstraZeneca |
| P206 | Reviewing the Relationship Between Nucleotide Structure and Desirable Characteristics | Sebastian | Sjöström | Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich |
| P207 | Red-light Controlled Regulation of Therapeutic Oligonucleotides | Marlen | Sahlbach | Goethe University |
| P208 | Targeted Delivery of Therapeutic Oligodeoxynucleotides to Plasmacytoid Dendritic Cells via Complexation with Natural β-(1→3)-D-Glucan (SPG) | Kazuo | Sakurai | University of Kitakyushu |
| P209 | Development of anti miR-21 oligonucleotide consisting of only SNA, an acyclic artificial nucleic acid | Fuminori | Sato | Grad. Sch. of Eng., Nagoya Univ. |
| P210 | Diligent design of antibody-antisense oligonucleotide conjugate architecture enables peripheral drug delivery to the brain | Felix | Schumacher | Roche |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P211 | Genome editing in mouse embryos at the single-cell stage uncovers previously undetected off-target sites and demonstrates distinct mutational profiles in individually edited cells | Niklas | Selfjord | Translational Genomics – Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca |
| P212 | Non viral based CRISPR-Mediated Gene Editing Strategies for Duchenne Muscular Dystrophy | Arun | Shastry | Dystrophy Annihilation Research Trusr |
| P213 | Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea | Hui Jin | Shin | Severance Hospital |
| P214 - V | Personalized Allele-Specific ASO treatment for GNAO1-Neurodevelopmental disorder | Inna | Shomer | Sheba Medical Center |
| P215 | Inhibition of Oligonucleotides Through Selective Photo-Tethering | Fabian | Sinsel | Goethe University |
| P216 | In vitro identification and efficacy of AIC468, a direct-acting anti-viral oligonucleotide against BK virus | Iris | van Wissen | Hybridize Therapeutics |
| P217 | Biodistribution of the 2'Ome PS ASO AIC468 in Mouse and Minipig | Janneke | Kouwenberg | Hybridize Therapeutics |
| P218 | Potential ASO treatment for CMT2S caused by IGHMBP2cryptic splice variant. | Sandra | Smieszek | Vanda Pharmaceuticals |
| P219 | RNA therapy with TfR aptamer enhanced blood-brain barrier penetration for brain metastasis from Triple-negative Brest Cancer | Minsun | Song | Beckman Research Institute of City of Hope |
| P220 | Enhanced upregulation of SCN1A using oligonucleotides with different mechanisms of action | Jack | Stahl | University of Miami Center for Therapeutic Innovation |
| P221 | Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy | Tiberiu | Stan | Leiden University Medical Center |
| P222 | Development of LC-MS-based analytical methods for comprehensive identification and quantification of impurities and metabolites of GalNAc-conjugated siRNA | Yuchen | Sun | Division of Medicinal Safety Science, National Institute of Health Sciences |
| P223 | Efficient Method Development and Identification of Oligonucleotides Therapeutics Impurities | Risa | Suzuki | Shimadzu Corporation |
| P224 | Development of self-amplifying mRNA (Replicon) vaccine against COVID-19 and other applications | Kiyoshi | Tachikawa | Arcturus Therapeutics, Inc. |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P225 | A novel circular RNA-based therapeutical platform for infectious and non-infectious diseases | Marc | Talló-Parra | noctuRNA Therapeutics S.L. |
| P226 | RNAi-based modulation of JAK1 for the treatment of inflammatory skin diseases | Qi | Tang | University of Massachusetts Chan Medical School |
| P227 | VO659, a CAG repeat-targeting ASO, induces skipping of ATXN3 exon 10 resulting in a truncated protein lacking the disease-causing polyglutamine domain in SCA3 | Janwillem | Testerink | VICO Therapeutics |
| P228 | Pharmacokinetics and biodistribution of Oligonucleotide Transport Vehicle (OTV) using ultra-sensitive, plate-based bioanalytical methods. | Mai | Thayer | Denali Therapeutics, Inc. |
| P229 | Novel Methods for Sustainable Oligonucleotide Synthesis | James | Thorpe | McGill University |
| P230 | A G-quadruplex-Forming ASO to reduce Monoamine Oxidase B in Parkinson's disease | Marc-Antoine | Turcotte | University of Sherbrooke |
| P231 | Topical administration of siRNA therapeutics via STAR particles for dermatological intervention | Mohammad | Zain Ul Abideen | RNA Therapeutics Institute, University of Massachusetts Chan Medical School |
| P232 | Exon-skipping ASO targeting the MuSK-BMP pathway to increase Adult Hippocampal Neurogenesis | Anne | Valat | Bolden Therapeutics |
| P233 | Targeting MeCP2-Associated Disorders with miRNA Site-Blocking Oligonucleotides | Amanda | Vanderplow | Loyola University Chicago |
| P234 | Polo-like kinase 1-targeting RNA interference prodrugs against childhood cancer | Daria | Varyvoda | Karolinska Institutet |
| P235 | Investigating the interactions of oligonucleotide phosphorothioate groups with RNA-binding proteins | Mathilde | Vincent | ETH Zürich |
| P236 | The novel design strategy of DNA-artificial nucleic acid chimera toward enhancement of RNA cleavage activities: application for COVID-19 therapeutics | Takehiko | Wada | IMRAM, Tohoku Univ. |
| P237 | Exploring small RNA isoforms as a treatment for Idiopathic Pulmonary Fibrosis (IPF) | Johnny | Wang | Gatehouse Bio |
| P238 | Development of a UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS & FTD | Wen-Hsuan | Chang | AcuraStem |
| P239 | RNA-PROTACs targeting disease-associated RNA-binding proteins | Céline | Weller | ETH Zürich |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P240 | Inventing Novel CRISPR-Cas9 Alternatives for Therapeutic Applications | Adam | White | Wake Forest University School of Medicine |
| P241 | Evaluation of antisense oligonucleotide therapy for neurodevelopmental disorders | Kim | Wijnant | Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center |
| P242 | Process for developing optimized siRNA conjugates for in vivo delivery. | sean | McCauley | Advirna |
| P243 | RISC PK Profile of 5'p-antisense strand in wildtype mouse shows good correlation with RISC-PK/ PD in AAV-HBV mouse model | Rui | Xu | Janssen Research & Development |
| P244 | Higher-Order Structure (HOS) Analysis of CBN-Binding DNA Aptamer using CD Spectroscopy | Ai | Yamane | JASCO Corporation |
| P245 | Morpholino/RNA heteroduplex via CSF route boosts splice switching activity without compromising safety | Mitsugu | Yanagidaira | Tokyo Medical and Dental University |
| P246 | From rodents to non-human primates, development of heteroduplex oligonucleotides to overcome CNS-toxicity of ASO with intrathecal injection. | Kotaro | Yoshioka | Department of Neurology and Neurological Science, Tokyo Medical and Dental University |
| P247 | From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation | Yuanyuan | Yu | Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), Hong Kong Baptist University |
| P248 | Exon-inclusion strategies for PLP1-associated hypomyelination of early myelinating structures | Bianca | Zardetto | Department of Human Genetics, Leiden University Medical Center |
| P249 | Retroelement Profiling Reveals Diagnostic and Therapeutic Opportunities in Neurodegenerative Disorders | Boxun | Zhao | Boston Children's Hospital |
| P250 | Retroelement Profiling Reveals Diagnostic and Therapeutic Opportunities in Neurodegenerative Disorders | Boxun | Zhao | Boston Children's Hospital |
| P251 | A High-Throughput, Hypothesis-Free Screening Platform for Precise Delivery of Nucleic Acid Therapeutics via Conjugates | Omer | Ziv | Eleven Therapeutics |
| P252 | Efficacy of customized Antisense Oligonucleotide Treatment for CLN7 Batten Disease: A Postmortem Analysis. | Aikaterini | Chatzipli | Division of Genetics and Genomics, Boston Children's Hospital |
| P253 | Utilizing RNA Hacking Technique to Suppress Gene Expression Levels | Yousuke | Katsuda | Kumamoto University |
| P254 | Induced cellular uptake of antisense oligonucleotide via Transient Receptor Potential C3/C6 activation | Hiroto | Kohashi | Graduate School of Pharmaceutical Sciences, Osaka University |

# 2023 Poster Index

**2023 Oligo Meeting | Barcelona | Spain**

| Poster # | Title | First Name | Last Name | Afilliation |
|---|---|---|---|---|
| P255 | A new strategy for DMD exon skipping with RNA-DNA hetero-G4 structure inducing ASOs | Ryo | Iwase | Department of Neurology and Neurological Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University |
| P256 | Effect of bridged nucleic acid introduction on the flexibility of oligonucleotides | Tomoka | Akita | Faculty of Frontiers of innovative Research in science and technology, Konan university |
| P257 | Strategy of chemical modification to overcome late-onset neurotoxicity of gapmer antisense oligonucleotide | Takayuki | Kuroda | Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University |
| P258 | Optimization of Antisense Oligonucleotides with Chemical Modifications Through Deep Learning for IDO1 Gene Regulation | Gyeongjo | Hwang | Spidercore Inc. |
| P259 | Domain Skipping in Nebulin as a Novel Therapy for Δexon55 Neb Related Nemaline Myopathy | Zach | Coulson | University of Toronto |
| P260 -V | Room Temperature Stabilization and Dual-Responsive Controlled Release of mRNA by a Multi-Layered Nucleic Acid Nanocapsule | Suman | Pal | University of Connecticut |
| P261 -V | Determining the cellular internalization mechanism and role of chemical structure on the gene regulation capabilities of nucleic acid nanocapsules | Jessica | Rouge | University of Connecticut |
| P262 -V | microRNA-21 blockade in human triple negative breast cancer allografts stopped progression and reduced immune checkpoint proteins | Eric | Wickstrom | Bound Therapeutics LLC |
| P263 -V | Forging a pre-clinical pipeline for N=1 splice-modulating antisense oligonucleotide therapies for rare genetic neuromuscular and neurodevelopmental disease | Katharine | Zhang | Children's Medical Research Institute |
| P264 | Amphiphilic and unsaturated lipid conjugates enable functional uptake of siRNAs in brain tumors in vivo | Samantha | Sarli | Umass Chan Medical School |